Full Text
PCN99 COST-EFFECTIVENESS OF IMATINIB AS ADJUVANT TREATMENT FOR RESECTED GASTROINTESTINAL STROMAL TUMORS (GIST) VERSUS BEST SUPPORTIVE CARE- CANADIAN PERSPECTIVE

Abstract

Authors

Ouagari K El V Pawar J Coombs J Rubin

Back to Volume 13, Issue 7
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×